Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed

Active, not recruiting

Conditions: Melanoma

First Posted Date: 2018-12-11

Last Posted Date: 2021-09-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 152

Registration Number: NCT03771859

Locations: 🇱🇺
Local Institution, Luxembourg, Luxembourg

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

Phase 2

Withdrawn

Conditions: Circulating Tumor DNA
Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma

Interventions: Biological: Nivolumab
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Docetaxel
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Other: Observation

First Posted Date: 2018-12-10

Last Posted Date: 2022-03-24

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03770299

A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Other: Non-Interventional

First Posted Date: 2018-12-07

Last Posted Date: 2020-03-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 264

Registration Number: NCT03769558

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

Phase 2

Completed

Conditions: Acute Ischemic Stroke
Transient Ischemic Attack (TIA)

Interventions: Other: Placebo
Drug: BMS-986177
Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2018-12-06

Last Posted Date: 2023-06-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2366

Registration Number: NCT03766581

Locations: 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Local Institution - 0019, York, Pennsylvania, United States
🇺🇸
Neurology Consultants of Dallas, PA, Dallas, Texas, United States

and more 358 locations

Evaluation of Safety and Effectiveness on Oral Anticoagulants

Completed

Conditions: Atrial Fibrillation

Interventions: Other: Non-Interventional

First Posted Date: 2018-12-05

Last Posted Date: 2022-05-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12354

Registration Number: NCT03765242

Locations: 🇯🇵
Local Institution, Minato-ku, Tokyo, Japan

A Taste Assessment of BMS-986165 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: Active Pharmaceutical Ingredient

First Posted Date: 2018-11-23

Last Posted Date: 2019-10-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9

Registration Number: NCT03751228

Locations: 🇺🇸
Senopsys, Woburn, Massachusetts, United States

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Biological: NKTR-214
Biological: Nivolumab

First Posted Date: 2018-11-19

Last Posted Date: 2021-10-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3

Registration Number: NCT03745807

Locations: 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan

An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165

First Posted Date: 2018-11-14

Last Posted Date: 2021-02-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT03739788

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

Completed

Conditions: Melanoma

Interventions: Other: Non-Interventional

First Posted Date: 2018-11-06

Last Posted Date: 2022-12-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 600

Registration Number: NCT03732560

Locations: 🇺🇸
Local Institution, Parsippany, New Jersey, United States

An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic

Phase 2

Completed

Conditions: Myocardial Failure
Congestive Heart Failure
Heart Decompensation
Cardiac Failure

Interventions: Drug: BMS-986231
Drug: Furosemide
Drug: Placebo

First Posted Date: 2018-11-05

Last Posted Date: 2021-02-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 23

Registration Number: NCT03730961

Locations: 🇬🇧
Richmond Pharmacology, London, United Kingdom
🇬🇧
Glasgow Clinical Research Facility, Glasgow, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy